ACIP dropped MMRV coverage. New data show it was a lifeline for VFC-eligible kids

I

In September 2025, the CDC's Advisory Committee on Immunization Practices (ACIP) voted to eliminate its recommendation—and Vaccines for Children (VFC) coverage—for the combined measles, mumps, rubella, and varicella (MMRV) vaccine in children younger than 4 years.¹ A new analysis of a decade of King County, Washington, immunization records suggests that decision may fall hardest on children who already face the greatest barriers to care.²

Investigators reviewing Washington State Immunization Information System data for more than 213,000 children born between 2014 and 2021 found that nearly 15% received MMRV as their first measles- or varicella-containing vaccine dose between 2015 and 2025, a share that held essentially flat across birth years despite ACIP's decade-old preference for coadministered MMR and varicella vaccine (MMR + VAR) as the default first dose.² Children who received MMRV first were significantly more likely to be Hispanic, Black, American Indian or Alaska Native, or Native Hawaiian or Pacific Islander; to be VFC-eligible; to be vaccinated at safety-net clinics; and to be receiving a catch-up dose after 15 months of age (P < .001 for all comparisons).²

Study design and key findings in King County children

The cross-sectional study used statewide registry data to classify first-dose selection—MMRV, coadministered MMR + VAR, MMR alone, or VAR alone—among King County residents aged 12 to 47 months.² Of 213,445 children included, 63.8% received coadministered MMR + VAR first, 17.8% received MMR alone, 14.7% received MMRV, and 3.7% received VAR alone.² Coadministered MMR + VAR use rose over the study period, from 61% of children born in 2014 to 67% of those born in 2021, while MMRV selection did not significantly change.² By age 4 years, 95% of the cohort had received both vaccine types, though children who initially received VAR alone were less likely to complete their MCV series (69%) than those who started with MMR alone (78%).²

ACIP's coverage decision and the 2009 febrile seizure data behind it

MMRV has carried a cautionary label since 2009, when ACIP responded to postmarketing data showing the first dose was associated with roughly double the risk of febrile seizures 5 to 12 days after vaccination, compared with separately administered MMR and varicella vaccines, in children aged 12 to 23 months.³ That evidence led ACIP to designate MMR + VAR the preferred first dose for children younger than 4 years while preserving MMRV as an option after clinician consultation.³ The September 2025 vote went further, removing the MMRV recommendation and its VFC eligibility for this age group entirely, alongside a companion action establishing a standalone toddler varicella pathway.⁴ The King County authors note that, to their knowledge, ACIP's public discussion did not include an Evidence to Recommendations analysis of which populations relied on MMRV.²

Equity implications for VFC-eligible and safety-net populations

The demographic pattern is what makes the coverage change notable for clinicians serving diverse or resource-limited populations. VFC-eligible children were more than 3 times as likely to have received MMRV first as non–VFC-eligible children (32.0% vs 9.2%), and children vaccinated at safety-net clinics were similarly overrepresented among MMRV recipients (35.9% vs 10.9% at non–safety-net sites).² Combination vaccines are generally associated with fewer injections and visits per series, a factor ACIP weighed in its 2010 MMRV recommendations.³ The authors cautioned that where visit time, vaccine inventory, and follow-up capacity are already constrained, narrowing first-dose options to two injections instead of one could add barriers to timely completion for VFC-eligible children specifically.²

Limitations and open questions

The analysis was limited to one Washington county and could not capture doses administered elsewhere; the authors caution results may not generalize to states without universal vaccine purchasing programs.² The study period also predates any measurable effect of ACIP's September 2025 action—it remains unknown whether removing MMRV from recommended, VFC-covered options will change overall completion rates, particularly among the safety-net and VFC-eligible populations who used it most. Continued registry surveillance could clarify whether completion disparities widen after implementation.²

References

1. Meeting of the Advisory Committee on Immunization Practices (ACIP): September 18 to 19, 2025, meeting summary. Centers for Disease Control and Prevention. Accessed July 8, 2026. https://www.cdc.gov/acip/downloads/minutes/summary-2025-9-18-19-508.pdf

2. Fagalde MS, Page LC, Marder EP, et al. Measles-containing vaccine use for children aged 12 to 47 months, 2015 to 2025. JAMA Netw Open. 2026;9(7):e2622734. doi:10.1001/jamanetworkopen.2026.22734

3. Marin M, Broder KR, Temte JL, Snider DE, Seward JF; Centers for Disease Control and Prevention (CDC). Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010;59(RR-3):1-12.

4. US Department of Health and Human Services. ACIP recommends standalone chickenpox vaccination for toddlers. Accessed July 8, 2026. https://www.hhs.gov/press-room/acip-recommends-chickenpox-vaccine-for-toddlers.html